Dear Editor,Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused the global outbreak of coronavirus disease 2019(COVID-19).By far,more than 35 million people had been infected by SARS-CoV-2,resulting ...Dear Editor,Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused the global outbreak of coronavirus disease 2019(COVID-19).By far,more than 35 million people had been infected by SARS-CoV-2,resulting in more than 1 million deaths globally.It is well recognized that SARSCoV-2 preferentially attacks pulmonary epithelial cells,leading to acute respiratory distress syndrome(ARDS).展开更多
The outbreak of coronavirus disease 2019(COVID-19)caused by the new virus SARS-CoV-2 has been announced as a public health emergency of international concern.1–3 The clinical features of patients with COVID-19 range ...The outbreak of coronavirus disease 2019(COVID-19)caused by the new virus SARS-CoV-2 has been announced as a public health emergency of international concern.1–3 The clinical features of patients with COVID-19 range from common fever and cough to other rare symptoms,such as diarrhea and nausea.This disease can progress quickly,and 2–3%of patients die within a short time,which is generally due to multiple organ failure.4–7 Clinically,COVID-19 patients are classified into mild,moderate,severe,and critical cases.5–7 The immune response against SARS-CoV-2 is probably linked to the severity of disease.Recently,Zheng et al.8 showed that elevated levels of T-cell exhaustion and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients;however,a more comprehensive understanding of the pathology of SARS-CoV-2 infection remains to be delineated.Here,we profiled immune cellular components using mass cytometry(CyTOF)to analyze the peripheral blood mononuclear cells(PBMCs)from patients with differences in disease progression by comparing with the PBMCs from healthy donors(HDs).展开更多
基金supported by the Ministry of Science and Technology of the People’s Republic of China(2020YFC0844900,2020YFC0841700,and 2020YFC0848700)the National Natural Science Foundation of China(81470566,81670765,81772165,and 81974303)+1 种基金the China Primary Health Care Foundation-Youan Medical Development Fund(BJYAYY2020PY-01)the funds from Neoline,Gbio and Quanterix。
文摘Dear Editor,Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused the global outbreak of coronavirus disease 2019(COVID-19).By far,more than 35 million people had been infected by SARS-CoV-2,resulting in more than 1 million deaths globally.It is well recognized that SARSCoV-2 preferentially attacks pulmonary epithelial cells,leading to acute respiratory distress syndrome(ARDS).
基金supported by the COVID-19 Key Technology Research and Development Funding of Beijing Hospital Authority,the National Natural Science Foundation of China(NSFC,81772165 and 81974303)the National 13th Five-Year Grand Program on Key Infectious Disease Control(2017ZX10202102-005-003)。
文摘The outbreak of coronavirus disease 2019(COVID-19)caused by the new virus SARS-CoV-2 has been announced as a public health emergency of international concern.1–3 The clinical features of patients with COVID-19 range from common fever and cough to other rare symptoms,such as diarrhea and nausea.This disease can progress quickly,and 2–3%of patients die within a short time,which is generally due to multiple organ failure.4–7 Clinically,COVID-19 patients are classified into mild,moderate,severe,and critical cases.5–7 The immune response against SARS-CoV-2 is probably linked to the severity of disease.Recently,Zheng et al.8 showed that elevated levels of T-cell exhaustion and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients;however,a more comprehensive understanding of the pathology of SARS-CoV-2 infection remains to be delineated.Here,we profiled immune cellular components using mass cytometry(CyTOF)to analyze the peripheral blood mononuclear cells(PBMCs)from patients with differences in disease progression by comparing with the PBMCs from healthy donors(HDs).
